CorMedix Inc. (CRMD)

Price$8.36

Value ScoreA

Growth ScoreA

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-22.71%

Price vs S&P 500 (4W)5.57%

VGM Score76.13

Market Capitalization$655.86M

P/E Ratio (Annual)4.02x

All Metrics

P/CF (Annual)3.75x

Book Value / Share (Quarterly)$5.57

P/TBV (Annual)34.93x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)1545.19%

Cash Flow / Share (Quarterly)$2.48

Price vs S&P 500 (YTD)-36.27%

Gross Margin (TTM)85.83%

Net Profit Margin (TTM)45.25%

EPS (TTM)$2.10

10-Day Avg Trading Volume1.09M

EPS Excl Extra (TTM)$2.10

Revenue Growth (5Y)319.48%

EPS (Annual)$2.03

ROI (Annual)29.59%

Gross Margin (Annual)88.46%

Net Profit Margin (5Y Avg)-13288.81%

Cash / Share (Quarterly)$2.27

P/E Basic Excl Extra (TTM)3.62x

Revenue Growth QoQ (YoY)226.05%

P/E Normalized (Annual)4.02x

ROA (Last FY)19.74%

Revenue Growth TTM (YoY)384.60%

EBITD / Share (TTM)$2.37

ROE (5Y Avg)-29.17%

Operating Margin (TTM)48.41%

Cash Flow / Share (Annual)$2.18

P/B Ratio1.50x

P/B Ratio (Quarterly)1.23x

Net Income / Employee (Annual)$853,700

EV / Revenue (TTM)1.56x

Net Interest Coverage (TTM)-1472.00x

ROA (TTM)27.37%

EPS Growth QoQ (YoY)38.69%

EV / EBITDA (TTM)3.04x

EPS Incl Extra (Annual)$2.03

Current Ratio (Annual)2.11x

Quick Ratio (Quarterly)2.59x

3-Month Avg Trading Volume1.43M

52-Week Price Return-36.57%

EV / Free Cash Flow (Annual)3.60x

P/E Incl Extra (TTM)3.62x

Revenue / Employee (TTM)$2,094,500

Tangible BV / Share (Quarterly)$0.87

P/S Ratio (Annual)2.10x

Asset Turnover (Annual)0.38x

52-Week High$17.43

Operating Margin (5Y Avg)-14116.51%

EPS Excl Extra (Annual)$2.03

CapEx CAGR (5Y)83.04%

Tangible BV CAGR (5Y)50.24%

26-Week Price Return-14.78%

Quick Ratio (Annual)1.87x

13-Week Price Return32.70%

Total Debt / Equity (Annual)0.36x

Current Ratio (Quarterly)2.98x

Enterprise Value$622.66M

Revenue / Share Growth (5Y)241.15%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)31.16%

Revenue / Employee (Annual)$1,632,000

Inventory Turnover (Annual)1.93x

Pretax Margin (Annual)48.13%

Cash / Share (Annual)$1.87

3-Month Return Std Dev43.66%

Gross Margin (5Y Avg)60.08%

Net Income / Employee (TTM)$947,700

ROE (Last FY)40.23%

Net Interest Coverage (Annual)16.69x

EPS Basic Excl Extra (Annual)$2.03

P/FCF (TTM)3.37x

Receivables Turnover (TTM)3.82x

EV / Free Cash Flow (TTM)3.20x

Total Debt / Equity (Quarterly)0.33x

EPS Incl Extra (TTM)$2.10

Receivables Turnover (Annual)2.80x

ROI (TTM)38.65%

P/S Ratio (TTM)1.64x

Pretax Margin (5Y Avg)-14021.27%

Revenue / Share (Annual)$3.88

Tangible BV / Share (Annual)$0.33

Forward P/E22.54x

Price vs S&P 500 (52W)-60.94%

P/E Ratio (TTM)3.62x

EPS Growth TTM (YoY)831.56%

Year-to-Date Return-28.12%

5-Day Price Return-1.07%

EPS Normalized (Annual)$2.03

ROA (5Y Avg)-28.12%

Net Profit Margin (Annual)52.31%

Month-to-Date Return-0.95%

Cash Flow / Share (TTM)$-0.85

EBITD / Share (Annual)$1.88

Operating Margin (Annual)48.17%

LT Debt / Equity (Annual)0.36x

P/CF (TTM)3.32x

ROI (5Y Avg)-31.30%

P/E Excl Extra (TTM)3.62x

LT Debt / Equity (Quarterly)0.33x

EPS Basic Excl Extra (TTM)$2.10

P/TBV (Quarterly)7.86x

P/B Ratio (Annual)2.26x

Inventory Turnover (TTM)2.97x

Pretax Margin (TTM)46.25%

Book Value / Share (Annual)$5.11

Price vs S&P 500 (13W)24.44%

Beta1.50x

P/FCF (Annual)3.80x

Revenue / Share (TTM)$4.30

ROE (TTM)50.38%

52-Week Low$6.13

vGradeA

gGradeA

mGradeC

vgmGradeB

Show chart for

Earnings Surprise History

Q1 260.49est. 0.37

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.15

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
CRMDCorMedix Inc.	A	A	C	$8.36
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Cormedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases. The company's primary product, DefenCath, is being marketed in the United States and other key markets.